trial

Investigator Initiated Study - Asenapine Early Psychosis

NCTId NCT01968161
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Unknown
Enrollment 12 (estimated)
Sponsored by Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec
Primary completion 2014-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Unknown
Enrollment
12 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2013-10
Primary completion
2014-02
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Asenapine

Sponsors

Centre de Recherche de l'Institut Universitaire en Santé Mentale de QuébecLead Sponsor

Investigators

1
Marc-André Roy, MD,MSc,FRCPPrincipal Investigator

Sites

1 total
Québec, Canada

Facts & assertions

4 sourced
Enrollment
12
Phase
PHASE4
Primary Completion Date
2014-02
Status
UNKNOWN
relationships
The graph out of here
drug
Asenapine
drug
lead_sponsor
Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec
company
indication
Schizophrenia and Disorders With Psychotic Features
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Disorders
indication
investigator
Marc-André Roy, MD,MSc,FRCP
person